Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double ‐Blind, Randomized Controlled Trial

ConclusionUpadacitinib was superior to placebo and adalimumab for improving signs, symptoms and physical function in RA patients on background methotrexate, and significantly inhibited radiographic progression versus placebo, while the overall safety profile was generally similar to adalimumab, except for higher rates of herpes zoster and CPK elevations on upadacitinib.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - July 8, 2019 Category: Rheumatology Authors: Roy Fleischmann, Aileen L Pangan, In ‐Ho Song, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J Ostor, Yihan Li, Yijie Zhou, Ahmed A Othman, Mark C Genovese Tags: Full Length Source Type: research